- $99.56m
- $40.32m
- $237.26m
Brief: Vaxart Receives Letter From Nasdaq On Regained Compliance With Minimum Bid Price Requirement
Vaxart Inc reports results for the quarter ended in March - Earnings Summary
Brief: Vaxart posts Q1 basic EPS USD -0.19
Vaxart Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Vaxart Receives Notice Of Delisting Or Failure From Nasdaq
Brief: Vaxart Inc Files For Mixed Shelf Of Up To $200 Million - SEC Filing
Vaxart Inc reports results for the quarter ended in December - Earnings Summary
Brief: Vaxart Provides Business Update And Full Year 2022 Financial Results
Vaxart Inc expected to post a loss of 23 cents a share - Earnings Preview
Vaxart Inc expected to post a loss of 23 cents a share - Earnings Preview
Vaxart Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Vaxart Doses First Subject In The Phase 2 Clinical Trial Of Its Bivalent Norovirus Candidate
Brief: Vaxart Names Phillip Lee As Chief Financial Officer
Brief: Vaxart Announces Collaborative Funding From Leading Foundation To Study Its Norovirus Vaccine Candidate In Breastfeeding Mothers
Brief: Vaxart Provides Business Update, Reports Third Quarter 2022 Financial Results
Vaxart Inc reports results for the quarter ended in September - Earnings Summary
Vaxart Inc expected to post a loss of 24 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Pfizer, Nvidia, Boeing, SAIC, BioAffinity, Polestar
U.S. STOCKS ON THE MOVE-Kroger, J.Jill, Twin Disc, Abbvie